HearingMed Conducts Clinical Trial for New Laser Tinnitus Therapy

HearingMed Conducts Clinical Trial for New Laser Tinnitus Therapy

Editor: You might have heard of low level laser as a tinnitus treatment. Here’s a notice about a research study that took place in California. I’m hoping we’ll be able to share the results of this study with you!

HearingMed, Inc, Roseville, Calif, a provider of hearing health services, is hosting an FDA clinical trial in Sacramento, Calif, exploring the use of laser therapy to moderate or eliminate the symptoms of tinnitus. The trial is sponsored by Erchonia Medical, Inc, a provider of low-level medical lasers.

“We are pleased to bring this clinical trial to Sacramento, said Mark Moore, President of HearingMed. “We feel that this cutting-edge technology may offer a real therapeutic alternative to those who suffer from this chronic and often severe condition. Our personal experience with Erchonia lasers convinced us to host this double-blind, placebo-controlled, randomized clinical trial.”

More than 50 million Americans suffer from some degree of tinnitus, according to the American Tinnitus Association. This often chronic condition is associated with a ringing in the ears or perception of sound where there is none. Causes of this condition are complex and are not well understood.

The trial will explore how low-level laser therapy may moderate or eliminate the symptoms of tinnitus. Individuals suffering from this condition, who have an interest in being a part of this trial are invited to apply in person at the McDonald Hearing Aid Center, located at 2344 Butano Drive, Suite C3, Sacramento, Calif. Prospective participants just need to show up between 9 a.m. and 4 p.m. on August 20, 21, or 22 to be assessed to see if they qualify for participation. Appointments are not required.

The trial will take approximately two weeks and will consist of two office visits, self-treatments administered at home and follow-up phone calls to measure results. There is no cost associated with participation in this trial.

“We are gratified by the informal response that we have already received from friends and our tinnitus patients who have expressed an interest in participating,” said Moore. “HearingMed and Erchonia are both fully committed to developing a positive new therapy for this difficult condition.”